GSK beats Q3 earnings estimates and reaffirms 2026 outlook
FROM THE WIRE · SEEKINGALPHA.COM
GSK beats Q3 EPS estimates as specialty medicines drive growth despite vaccine weakness.
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishAn EPS beat driven by specialty medicines and a reaffirmed 2026 outlook supports the shares of a large pharma group.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01GSK beat third-quarter EPS estimates.
- 02Growth was driven by specialty medicines while vaccines weakened.
- 03The company reaffirmed its 2026 outlook.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets